Skip to main content

Lung and thoracic cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews top story

Local ablative therapy–pembrolizumab benefit suggested for metastatic NSCLC

Lung cancer illustration

Data from two phase II studies published in JAMA Oncology lend support to the sequential use of local ablative therapy and PD-1 blockade in patients with metastatic non-small-cell lung cancer.

medwireNews top story

CTCs prognostic in limited-stage SCLC

Cancer cells

The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.

medwireNews top story

Whole-body MRI staging quicker and cheaper than standard pathways in NSCLC

Patient in scanner

The Streamline L trial has found that in patients with newly diagnosed non-small-cell lung cancer, a staging pathway using whole-body magnetic resonance imaging has similar accuracy but a shorter time to complete staging and lower mean per-patient costs versus standard pathways.

medwireNews top story

Immunotherapy-related AEs reviewed, underlying mechanism postulated

Cancer cell

Researchers have comprehensively analyzed the incidence of adverse events in trials of PD-1 and PD-L1 inhibitors, while another team has provided insight into the potential pathophysiologic process underlying these effects.

Expert opinion

Immunotherapy for patients with metastatic NSCLC harboring an EGFR mutation

DNA samples

Management of EGFR-mutant non-small-cell lung cancer has been dominated by targeted therapies, but it is less clear where immunotherapy will fit into the treatment paradigm. Charu Aggarwal (University of Pennsylvania, USA) explores the current place of immunotherapy in treating this disease.

Expert opinion

Management of EGFR mutation-positive NSCLC: Two steps forward, looking back

Adenocarcinoma histology

Caroline McCoach (Helen Diller Family Comprehensive Cancer Center, CA, USA) and Howard (Jack) West (Swedish Cancer Institute, WA, USA) discuss the way forward after great progress with tyrosine kinase inhibitors targeting the epidermal growth factor receptor in non-small-cell lung cancer.

Expert opinion

Choosing an immunotherapy approach in patients with advanced NSCLC

Advanced NSCLC

Liza Villaruz (Hillman Cancer Center, PA, USA) examines recent KEYNOTE trials investigating pembrolizumab for advanced non-small-cell lung cancer and the questions they raise regarding patient selection and combination therapy.

View from the clinic

Explaining immunotherapy to our patients with NSCLC

Explaining immunotherapy

Immunotherapy is changing practice in lung cancer, and with this, patient education. In this 'View from the clinic' article, Advisory Board member Beth Eaby-Sandy (Abramson Cancer Center, PA, USA) describes how she explains the new immunotherapy treatments to her patients. 

19-06-2019 | Radiotherapy | ASCO 2019 | Article

Researcher comment: Fewer AEs with proton versus photon radiotherapy

Brian Baumann presents their comparative analysis of the adverse event profiles of proton and photon radiotherapy in nonmetastatic patients receiving chemoradiotherapy with curative intent for various solid tumors, including lung cancer (5:28).

18-06-2019 | CNS metastases | Video | Article

Managing brain metastases in lung cancer

Brain metastases are a common complication of lung cancer and are associated with significant morbidity and mortality. In this video, Manmeet Ahluwalia provides a neuro-oncologist's perspective on managing lung cancer patients who develop these metastases. 

These videos were made possible by independent educational funding provided by AstraZeneca.

13-06-2019 | Screening | ASCO 2019 | Article

Researcher comment: Screening underserved groups with the Lung Bus

Mellisa Wheeler talks about how their mobile low dose-CT lung scanning unit – the Lung Bus – is helping to reach underserved populations in North Carolina, USA. She also comments on the issues of access to care and overscreening, and outlines the next steps (3:54).

04-06-2019 | Non-small cell lung cancer | ASCO 2019 | Article

Expert comment: 5-year update of KEYNOTE-001

ASCO expert David Graham tells us just why he thinks the 5-year survival data from the advanced non-small-cell lung cancer patients enrolled in the phase Ib KEYNOTE-001 trial are so remarkable (1:26).

03-06-2019 | Non-small cell lung cancer | ASCO 2019 | Article

Researcher comment: 5-year KEYNOTE-001 results show long-lasting survival for some advanced NSCLC patients

Edward Garon presents the 5-year follow-up results of the advanced non-small-cell lung cancer cohort of the phase I KEYNOTE-001 trial of pembrolizumab monotherapy (4:12).

01-06-2019 | Lung cancer | ASCO 2019 | Article

Expert highlights: Lung cancer at ASCO 2019

Advisory Board member Ross Camidge comments on his picks for the most exciting lung cancer research being presented at the 2019 ASCO Annual Meeting, including the RELAY trial and the ARROW trial of the RET inhibitor BLU-667 (3:13).

28-02-2019 | Lung cancer | At a glance | Article

At a glance: CheckMate lung cancer trials

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

28-01-2019 | Immunotherapy | Podcast | Audio

Understanding the relationship between the gut microbiome and immunotherapy

Jennifer Wargo, from The University of Texas MD Anderson Cancer Center in Houston, USA, shares her insights into recent research showing an association between intestinal microbiota and response to immunotherapy (13:27).

12-12-2018 | Immunotherapy | Feature | Article

Hyperprogression as a response to immunotherapy: ‘A serious downside’

In light of recent reports of hyperprogression in response to treatment with cancer immunotherapy, medwireNews spoke to medical oncologist Razelle Kurzrock (University of California, San Diego, La Jolla, USA) about the phenomenon, the implications for therapy, and future directions for research.

Our Editorial Board advisor

Fiona Blackhall MD, PhD

Dr Blackhall is a Professor of Thoracic Oncology with expertise in personalized medicine and circulating biomarkers within the Institute of Cancer Studies, University of Manchester and has been a Consultant Medical Oncologist at The Christie Hospital, Manchester since 2005. She has conducted over 50 therapeutic clinical trials, including practice-changing precision medicine studies, and led on new directions in radiotherapy-related research and supportive palliative care research.

Journal articles and book chapters

17-06-2019 | Small-cell lung cancer | Article

Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential

Armstrong SA & Liu SV. Adv Ther 2019. doi:10.1007/s12325-019-01008-2

08-11-2018 | Non-small cell lung cancer | Article

Risk factors for brain metastases in patients with non–small‐cell lung cancer

Ning An, Wang Jing, Haoyi Wang, Ji Li, Yang Liu, Jinming Yu, Hui Zhu. Cancer Med 2018;7(12): 6357-6364. doi:10.1002/cam4.1865.

21-10-2018 | Non-small cell lung cancer | Article

Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors

Wrona A et al. Cancer Treat Rev 2018; 71: 59–67. doi:10.1016/j.ctrv.2018.10.011.

14-08-2018 | Non-small cell lung cancer | Article

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Recondo G et al. Nat Rev Clin Oncol 2018. doi:10.1038/s41571-018-0081-4

03-07-2018 | Non-small cell lung cancer | Article

Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection

Abbosh C et al. Nat Rev Clin Oncol 2018. doi:10.1038/s41571-018-0058-3


01-02-2017 | Immunotherapy | Primer | Collection

The fundamentals of cancer immunotherapy

A introductory guide to cancer immunotherapy for non-specialists, focusing primarily on the mechanisms of immune checkpoint inhibition and the role of these agents in anticancer therapy.

12-04-2018 | EGFR signalling | Primer | Collection

EGFR signaling in cancer

This downloadable powerpoint slide set includes a variety of high quality illustrations relating to the role of the epidermal growth factor receptor pathway in the pathogenesis and progression of cancer and as a target for anti-cancer therapy.

28-02-2019 | Lung cancer | At a glance | Article

At a glance: CheckMate lung cancer trials

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

Image Credits